Table 1 Summary of studies reporting non-cardiac surgery following percutaneous coronary intervention

Study	Year	Patients	Stent type	Antiplatelet therapy	Perioperative therapy	Outcome
Kaluza et al6	2000	40	BMS	Aspirin + ticlopidine	Most discontinued both agents	20% Mortality within 4 weeks of stenting
Wilson et al7	2003	207	BMS	Aspirin + warfarin or ticlopidine or clopidogrel	26% Continued dual therapy	4.8% MI/stent thrombosis within 6 weeks, none after 6 weeks
Reddy/Vaitkus8	2005	56	BMS	Aspirin + clopidogrel	60% had MACE on clopidogrel at surgery	14% MACE within 6 weeks of stenting, none after 6 weeks
Sharma et al9	2004	47	BMS	Aspirin + ticlopidine or clopidogrel	25% Stopped thienopyridine within 3 weeks of stenting	85% Mortality within 3 weeks if antiplatelet agents stopped, few events beyond 3 weeks
Compton et al13	2006	38	DES	Aspirin + clopidogrel	41% Receiving clopidogrel at time of surgery	0% Event rate, relatively late surgery (median 260 days)
Kim et al14	2007	239	BMS/DES	Aspirin + clopidogrel	Stopped 5–7 days before elective surgery	2.2% MACE DES group, 0% BMS group

BMS, bare metal stent; DES, drug-eluting stent; MACE, major adverse cardiac event; MI, myocardial infarction.